Abstract
While a time-kill methodology noted no appreciable improvement in bactericidal activity with the addition of azithromycin (AZM) to a ceftazidime (CAZ) regimen, data from the murine pneumonia model showed that the addition of AZM significantly improved survival compared to treatment with CAZ alone. These data suggest that AZM might be a useful adjunctive therapy in the management of pneumonia resulting from mucoid isolates of Pseudomonas aeruginosa.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Azithromycin / pharmacology
-
Azithromycin / therapeutic use*
-
Ceftazidime / therapeutic use
-
Cephalosporins / therapeutic use
-
Colony Count, Microbial
-
Drug Therapy, Combination
-
Humans
-
Mice
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / microbiology
-
Survival Analysis
-
Time Factors
-
Urinary Tract Infections / microbiology
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Azithromycin
-
Ceftazidime